The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation with a focus upon translating discoveries into therapies in humans.
He has an H-index of 48 and i10-index of 158 (Google scholar), and his work has been cited >8100 times, with publications in journals such as the NEJM, Circulation, Journal of the American college of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes. His work is diverse covering clinical guidelines statements, clinical trials, and preclinical studies along the themes of ventricular remodeling, diabetes, magnetic resonance imaging and echocardiography. He is a member of the editorial board of various journals such as The Canadian Journal of Cardiology and Cardiovascular Diabetology. He has received funding from the Heart and Stroke Foundation Canada, CIHR, Canadian Foundation of Innovation, Ministry of Ontario and industry sources, totally >$5 million as principal investigator. As a co-investigator, he has been part of >$20 million in funding, from the Ministry of Ontario, HSF, CIHR, CFI and industry sources.
Dr Connelly has been recognised for his contributions to science by being awarded a HSF clinician scientist award, a CIHR New Investigator Award, an Early Researcher Award from the Ministry of Ontario, the SC Verma award and the Insulin 100 emerging leader award to celebrate 100 years since the discovery of insulin at University of Toronto, as well as Canadian Cardiovascular Congress YIA 2012. He is current chair of the Canadian Cardiovascular guideline and was chair of the macrovascular complication section for Diabetes Canada CPG 2018.
Dr. Kim Connelly is the director of the Keenan Research Centre for Biomedical Science and holds the Keenan Chair in Research Leadership.